메뉴바로가기 본문바로가기

human vaccine

인류의 안전과 건강 증진에 기여하는 기업, (주)인테라입니다.

Human Vaccine

01Norovirus Vaccine
Norovirus is highly contagious and the leading cause of acute gastroenteritis worldwide.
Norovirus related acute gastroenteritis

Acute nausea, uncontrolled vomiting and diarrhea

highly contagious and resistant to environmental condition

hundreds of millions of cases each year with up to 200,000 deaths in children < 5 years of age

Potential market : Military, School, Hospital & Traveler..

Unmet needs of norovirus vaccine

Lack of in vitro culture system VLP is the only means for vaccine development

High genetic diversity : Five genogroup & minimum twenty five serotype Multivalent vaccine development is mandatory

Competitiveness of InThera’s Norovirus vaccine

Production of VLP in E.coli through the use of platform technology, RIPT.

High-yield and fast manufacturing of VLP with cost-effectiveness

Development of multivalent vaccine against multiple strains of norovirus

02Hand, Foot and Mouth Disease (HFMD) Virus Vaccine
Worldwide viral infectious disease in infants and young children
Associated with the severe neurologic complication and high morbidity and mortality
Vaccine is urgently needed to prevent and control the epidemics of HFMD.
Hand, Foot and Mouth Disease (HFMD)

A febrile illness characterized by maculopapular rash or blisters on the hands, soles, and buttocks
and is associated with painful ulcerative lesions of the mouth.

Enterovirus 71 (EV71) and Coxsackievirus A16(COX A16) are the predominant cause of HFMD

EV71 is neurotropic virus responsible for severe CNS complication which is associated with high mortality

In recent years numerous outbreaks of HFMD has occurred and caused significant morbidity and mortality. (in 2010, 1.8 mil. cases and 905 deaths in China)

Unmet Needs of HFMD virus vaccine

In the absence of effective treatment, large scale HFMD outbreaks have a major impact on healthcare and daycare systems.

Highly contagious and genetic variability of EV71 & Cox A 16 multivalent vaccine development is mandatory

Competitiveness of InThera’s Norovirus vaccine

High-yield and fast production of VLP in E.coli through the use of platform technology, RIPT.

Development of multivalent vaccine against multiple strains of EV 71 & Cox A 16 virus.